Should the UK continue breast screening?
This article was originally published in Clinica
The value of the UK breast screening programme, heralded as a flagship for preventive medicine, is being questioned by one of its pioneers. Professor Michael Baum, research director of the Institute of Cancer Research, suggests that more lives might be saved by reallocating scarce cancer resources to drug research and other emerging treatments. Prof Baum has resigned from the government's NHS breast cancer screening advisory group to voice his concerns.
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.